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Microenvironmental niche divergence shapes
BRCA1-dysregulated ovarian cancer morphological
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How tumor microenvironmental forces shape plasticity of cancer cell morphology is poorly
understood. Here, we conduct automated histology image and spatial statistical analyses in
514 high grade serous ovarian samples to deﬁne cancer morphological diversiﬁcation within
the spatial context of the microenvironment. Tumor spatial zones, where cancer cell nuclei
diversify in shape, are mapped in each tumor. Integration of this spatially explicit analysis with
omics and clinical data reveals a relationship between morphological diversiﬁcation and the
dysregulation of DNA repair, loss of nuclear integrity, and increased disease mortality. Within
the Immunoreactive subtype, spatial analysis further reveals signiﬁcantly lower lymphocytic
inﬁltration within diversiﬁed zones compared with other tumor zones, suggesting that even
immune-hot tumors contain cells capable of immune escape. Our ﬁndings support a model
whereby a subpopulation of morphologically plastic cancer cells with dysregulated DNA
repair promotes ovarian cancer progression through positive selection by immune evasion.
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P lasticity of cancer nuclear shape is essential for cells toassume a variety of critical functions such as migration andmetastasis1,2. Both external signals from the micro-
environment and internal changes in the nuclear envelope com-
ponents can trigger alterations in nucleus shape2–4, and
deregulate important pathways such as DNA repair5–7. Con-
versely, cancer cells can actively engage in overcoming micro-
environmental constraints such as tissue stiffness8,9 by adapting
their shapes. Although nuclear shape irregularity is routinely
assessed in diagnostic histology and the nuclear envelope is under
intense investigation, little is known about the microenviron-
mental signals that shape cancer nuclear morphology in human
tumors in situ. This is largely due to difﬁculties in reproducing
complex human tumor microenvironments in vitro, and a lack of
quantitative large-scale data on cancer morphology and spatial
variability of the human tumor microenvironment.
Changes in expression of nuclear envelope components
including Lamin A/C10–12, Emerin13, and NUP8814 have been
identiﬁed in ovarian cancer. High-grade serous ovarian cancer
(HGSOC) is the most common histological subtype of
ovarian cancer, with a staggeringly low ﬁve-year survival rate of
30–40%15,16. Previously, we proposed a HGSOC subtyping
method based on the abundance of stromal cells and lymphocytes
in histology samples17. Genomic analysis also revealed prognostic
molecular subtypes with distinct microenvironmental features
such as the Immunoreactive subtype18,19. However, inﬂuences
from the microenvironment should be regional, dictated by the
high spatial heterogeneity in solid tumors20–22. Conventional
histology and genomic analysis typically do not reveal spatially
explicit information about the microenvironment. Therefore, how
regional differences in microenvironmental selective pressures
actively shape cancer nuclear morphology has not been studied.
Unbiased, large-scale analysis of cancer morphology within the
spatial context of the local microenvironment has the potential to
generate more powerful predictive models and identify new tar-
gets for this aggressive cancer type. Such studies can offer new
understanding into the adaptive advantage of cancer morpholo-
gical plasticity, akin to understanding the morphological diversity
of a species across geographical locations in ecology.
In this paper, we developed a new way of studying how
microenvironmental niches shape cancer nuclear morphology by
combining machine learning, digital pathology and spatial sta-
tistics. Integration of morphological and molecular data in 514
HGSOC tumors: 1) led to the identiﬁcation of cancer morpho-
logical diversiﬁcation as a spatial measure implicated in dereg-
ulation of DNA repair, loss of nuclear integrity and increased
disease mortality; 2) provided empirical evidence that a sub-
population of cancer cells with morphological diversiﬁcation
could possess a selective advantage in locally immunosuppressive
microenvironments; 3) supports a model of morphological plas-
ticity as a tumor ecological process with profound clinical
implications.
Results
Spatial mapping of morphological diversiﬁcation. To enable
single-cell classiﬁcation of hematoxylin & eosin (H&E)-stained
whole-tumor histology slides for HGSOC, we developed an image
processing pipeline, building on our previous studies17,23
(Methods, ﬁg. 1a). Stain normalization24 and automated artefact
detection were implemented to account for the high levels of
variability in The Cancer Genome Atlas (TCGA)25 images. On
average, 184,541 cancer cells (standard deviation ± 152,271),
34,923 lymphocytes (±31,114) and 39,610 stromal cells (±35,443)
were identiﬁed, with quantitative morphological analysis, in each
whole-section sample. A total of 106,620,458 cancer and
40,559,923 microenvironmental cells was identiﬁed in the entire
cohort. We subsequently tested the accuracy of our pipeline with
ﬁve orthogonal data types. First, the balanced accuracy as an
average of speciﬁcation and sensitivity of our classiﬁer was 80.6%
for stromal cells, 85.0% for cancer cells, and 82.6% for lympho-
cytes (ﬁg. 1b, Methods). Secondly, automated cell scoring using
image analysis was highly correlated with the independent scor-
ing provided by TCGA pathologists (ﬁg. 1c) (lehirdly, using gene
expression data and enrichment analysis26–28, we identiﬁed sig-
niﬁcant associations between cell abundance and relevant func-
tional pathways and biological processes including cell cycle and
checkpoints for cancer cells, chemokine and leukocyte transen-
dothelial migration for lymphocytes, and matrisome and collagen
formation for stromal cells (Supplementary Table 1), supporting
the biological relevance of the image analysis results. Next, tumor
purity measures from gene expression-based method ESTIMATE
and copy number-based ABSOLUTE correlated with tumor cel-
lularity estimated by image analysis (ESTIMATE Spearman’s
rho= 0.44, p= 0; ABSOLUTE, rho= 0.43, p= 0). These corre-
lations were higher than the correlations between molecular
measures and pathologists’ scores (Spearman’s rho= 0.31 for
ABSOLUTE and pathologist, rho= 0.35 for ESTIMATE and
pathologist). Finally, high spatial and sample-level correlations
between H&E-based estimates and immunohistochemistry (IHC)
sections of cancer, lymphocyte, and stromal markers on a vali-
dation set further demonstrated the validity of automated H&E
image analysis (Fig. 1d–f, Supplementary Data 1, Supplementary
Figure 1 and Methods).
Based on the morphological features and spatial distribution of
cancer cells, we used spatial tessellation to partition tumors into
non-overlapping zones, followed by a spatial statistical signiﬁ-
cance test to identify zones where cancer nuclei diversiﬁed in
shape (Methods, Fig. 1g). On average, there were 20 diversiﬁca-
tion zones (±8) per tumor when diversiﬁcation was present, and a
diversiﬁcation zone contains 350 (±194) cancer cells. 53.3% of the
tumors (276/514) presented at least one morphological diversi-
ﬁcation zone.
Disruption of nuclear envelope integrity in diversiﬁed tumors.
We ﬁrst tested if known relevant nuclear envelope components in
ovarian cancer were deregulated according to cancer nuclear
morphological diversiﬁcation, including LMNA, Lamin B1 and
B2, Emerin, nucleoporins NUP88 and NUP1532. The presence of
morphological diversiﬁcation zone was associated with increased
expression of LMNA and decreased expression of NUP88 and
NUP153 (Fig. 2a), although not with LMNB1/2 or Emerin
expression (p > 0.05, Kruskal–Wallis test). These associations
remained signiﬁcant in whole transcriptome differential expres-
sion analysis after multiple testing corrections (Supplementary
Data 2). However, within the diversiﬁed patient group, the frac-
tion of diversiﬁed zones among all zones did not further correlate
with the expression level of these genes (p > 0.05). In addition,
tumors presented with at least one morphological diversiﬁcation
zone were less likely to be immune-high tumors based on
microenvironmental composition from histology image analysis
(Fig. 2b, Supplementary Figure 2). Consistent with this, less
Immunoreactive (p= 5.37 × 10-6, Fisher’s test) tumors were
found to present morphological diversiﬁcation (Fig. 2b). On the
other hand, our classiﬁcation of morphological diversiﬁcation
presence was not inﬂuenced by tumor size, debulking status, and
tumor cellularity (Supplementary Figure 3).
We then sought to determine the clinical implication of
morphological diversiﬁcation in HGSOC. In both TCGA cohorts
deﬁned by contributing sites, presence of morphological diversi-
ﬁcation was associated with poor overall survival (OS) but not
ARTICLE NATURE COMMUNICATIONS | DOI: 10.1038/s41467-018-06130-3
2 NATURE COMMUNICATIONS |  (2018) 9:3917 | DOI: 10.1038/s41467-018-06130-3 | www.nature.com/naturecommunications
a TCGA H&E whole-tumor slides n=514
b
Stain normalization Cell classification
d
Spatial vorronoi tesselation
Mapping morphological diversification 
Moran’s I significance test Morphological
diversification zone
Original Classified
Cancer
Lymphocytes
Stromal
0.3
0.4
0.5
0.6
0.7
0.8
0.9
Cancer cell fraction by pathologists
Ca
nc
er
 c
el
l f
ra
ct
io
n 
by
 im
ag
e 
an
al
ys
is
<30 30−50 50−70 >70
0
10
20
30
40
50
p=0.001
<30 30−50 50−70 >70
c
Stromal cell fraction by pathologists
St
ro
m
al
 c
el
l f
ra
ct
io
n 
by
 im
ag
e 
an
al
ys
is
p=0.001
High
Low
Cancer nuclear
shape variability
0.8505
0.8262
0.8064
Balanced average
g
IHC image registration to H&E
CK7
SMA
H&E
CD3
CD20
H&E cancer density
e
H&E cancer positivity
SM
A-S
tro
ma
CK
7-C
an
cer
CD
3-L
ym
0.5
0.6
0.7
0.8
0.9
1
Sp
at
ia
l c
or
re
la
tio
n
Zone 1
Zone 2
Measure nuclear shape variability
p<0.05 
p≥0.05
High variabilityLow variability
Cancer
Lym
Stromal
CK7 CD3 SMA
1 0.162 –0.321
–0.296 0.710 0.592
–0.360 0.336 0.882
f
CK7 positivity
H&E cancer positivity
Fig. 1 Our computational pipeline for the identiﬁcation of cancer nuclear morphological diversiﬁcation zones. a H&E-stained whole-tumor section slides
were digitized and stain normalized. Single cells were classiﬁed based on their morphology. Voronoi tessellation was employed to subdivide the tumors into
polygons. Morphologically diversiﬁed zones were detected using local Moran’s I statistics. b An illustrative example of single-cell classiﬁcation: cancer cells
(green), stromal cells (red), and lymphocytes (blue). Nucleus boundaries were generated by automated image analysis. Accuracy was assessed using
balanced average, which is the mean of sensitivity and speciﬁcity. Scale bar shows 20 μm. c Jonckheere trend test of automated versus pathologist’s cell
abundance scoring of cancer cells and stromal cells as a second method for validation. Boxplot center line, bounds of box and whiskers represent here and
henceforth median, inter-quartile range and extreme values (1.5 times inter-quartile range). d Our image registration pipeline for validating H&E image
analysis using serial IHC sections. An example of overlaying H&E-based cancer identiﬁcation result (green points showing cancer-positive regions) on CK7
was shown. e Boxplot to show the spatial correlation between CK7 and H&E-based estimate of cancer cells, CD3 and lymphocytes, and SMA and stromal
cells in all IHC validation samples. f Spearman correlation of sample-level scores from H&E image analysis (Cancer%, Lymphocyte%, Stromal%) versus
IHC CK7, CD3 and SMA scores. g An illustrative example of running local Moran’s I analysis: a tumor section was spatially divided using Voronoi
tessellation; cancer cell nuclei in each zone analyzed with respect to shape variability; and the resulting heatmap of shape data superimposed with
signiﬁcance test results. Images are for illustrative purpose only and do not reﬂect actual size of the spatial zones. Heatmap colors represent shape
variability of cancer cell morphology in the spatial zone. Spatial zones identiﬁed to be morphologically diverse were outlined in green
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relapse-free survival (RFS) (Fig. 2c–d, OS Cohort 1: n= 156, p=
0.026, HR= 1.99 [1.08–3.66]; Cohort 2: n= 355, p= 0.016,
HR= 1.39 [1.06–1.81]). In comparison, morphological measures
that were not spatially explicit were not prognostic (mean,
median and standard deviation of the shape feature: all p > 0.1,
log-rank test), highlighting the importance of studying the spatial
variability in cancer morphology. Applying the same analysis to
lymphocytes and stromal cells showed no diversiﬁcation for
lymphocytes and less frequent (19%) diversiﬁcation for stromal
cells with no correlation with prognosis, indicating that
diversiﬁcation was predominately a clinically relevant aspect of
cancer cell biology. Multivariate analysis further demonstrated
the independent prognostic value of diversiﬁcation presence, after
adjusting for clinical variables including debulking status, age,
and microenvironmental features (Table 1). Importantly, the
fraction of diversiﬁed zones among all zones did not further
stratify the diversiﬁed patient group (p > 0.05, log-rank test).
Therefore, the presence, independently on the quantity, of
morphologically diverse cancer cells could indicate clinically
relevant intra-tumor heterogeneity. We henceforth focused on the
binary classiﬁcation of morphological diversiﬁcation based on the
presence instead of quantity of diversiﬁcation zones in this study.
Concordant deregulation of DNA repair in diversiﬁed tumors.
To decipher the molecular basis of morphological diversiﬁcation,
we examined transcriptional, copy-number, mutation and
methylation proﬁles in TCGA. A concordant down-regulation of
key homologous recombination DNA repair genes in diversiﬁed
samples was evident. Among the top 10 genes ranked by differ-
ential expression analysis, RAD54L, FANCG, and BRCA1 formed
a co-expression network module together with DNA damage
checkpoint CHEK1, cell cycle gene CCNA2, GINS2 in DNA
replication and centrosomal protein CEP76 (Fig. 3a–c, Supple-
mentary Data 2). Enrichment analysis revealed cell cycle and
DNA repair Gene Ontology terms in down-regulated genes for
diversiﬁed samples (Supplementary Data 3). Although copy
number or methylation data alone did not add further informa-
tion on DNA repair (Supplementary Data 4–5), their integration
with gene expression revealed strong cis-driven effects from
copy number alterations (p < 0.0001, ANOVA) but not methy-
lation (p > 0.05, ANOVA) on the down-regulation of RAD54L
and FANCG (Supplementary Figure 4). Among all 33 known
oncogenic and suppressive drivers reported in HGSOC29, only
BRCA1 expression was associated with cancer morphological
diversiﬁcation. In concordance with a previous report18, BRCA1
expression was lower in the epigenetically silenced group and
BRCA1 mutated samples compared with the non-silenced and
wildtype group, respectively (Fig. 3d–f). However, diversiﬁed
samples were not enriched for mutations in any gene or BRCA1
methylation (p > 0.05). This suggests that diversiﬁcation is a
morphological marker of DNA repair dysregulation.
Indeed, morphological diversiﬁcation could be used to further
stratify BRCA1-WT patients for OS and RFS (OS: p= 0.0016,
HR= 1.55 [1.18–2.04], RFS: p= 0.017, HR= 1.38 [1.06–1.80]),
but not the BRCA1-mutated group (p > 0.05, log-rank test,
Supplementary Figure 5. By merging BRCA1 and BRCA2
mutation status, we identiﬁed three major patient groups with
distinctly different prognosis: the BRCA1/2 mutated group with
the best prognosis (BRCA1/2-MUT compared with all other
samples: OS p= 2.82 × 10−5, HR= 0.44 [0.30–0.66]), the BRCA1/
2-WT and diversiﬁcation group with the worst prognosis (OS p
= 5.264 × 10−7, HR= 1.83 [1.44–233]), and the intermediate
BRCA1/2-WT without diversiﬁcation (e. BRCA1 and RAD54L
expression were signiﬁcantly lower in the BRCA1/2-WT,
diversiﬁed group than in the BRCA1/2-WT not-diversiﬁed group
and even the BRCA1/2-MUT group (Fig. 3h). Taken together,
these data emphasize the speciﬁcity of DNA repair dysregulation
as a major oncogenic process underlying morphological
diversiﬁcation.
Unifying tumor microenvironment, cancer morphology, and
genetics. Because morphological diversity has been associated
with genetic intra-tumor heterogeneity30,31, we investigated the
association between tumor morphological diversiﬁcation and
mutation burden (n= 297). Mutation burden was not sig-
niﬁcantly associated with diversiﬁcation (p= 0.079, Supplemen-
tary Figure 6A). However, high mutation burden was associated
with favorable OS and RFS (OS: p= 0.003, HR= 0.63
[0.47–0.86], RFS: p= 0.04, HR= 0.64 [0.47–0.87], Fig. 4a), which
may be explained by an increase of lymphocytic inﬁltration in
these samples (p= 0.003, Kruskal–Wallis test, Supplementary
Figure 6B). While mutation burden, lymphocytic inﬁltration, and
diversiﬁcation each held strong prognostic value, they indepen-
dently contributed to a combined model that was highly prog-
nostic (Fig. 4b–d, Supplementary Figure 7). This highlights an
opportunity for developing a clinical test to identify high-risk
patients by combining knowledge of tumor microenvironment,
cancer morphology and genetics.
Spatial interplay with lymphocytic inﬁltration. To further
investigate the interplay between cancer morphological plasticity
and the microenvironment, we focused on the Immunoreactive
subtype with the assumption that, in general, strong micro-
environmental inﬂuence existed in this subtype. Interestingly,
only within this subtype, diversiﬁcation was associated with
increased lymphocyte abundance (Fig. 5a, Supplementary Fig-
ure 8). Consistent with this, CIBERSORT32 analysis using gene
expression data revealed increased plasma cells (p= 0.022,
Kruskal–Wallis test) and, in smaller proportions, naïve B cells
(p= 0.034, Kruskal–Wallis test) in morphologically diversiﬁed
samples (Methods, Fig. 5b). Despite having an immune-hot
microenvironment, morphologically diverse tumors were more
aggressive, with 14.5% OS and 6.7% RFS at year 5 compared with
53.3% OS and 31.1% RFS for tumors without diversiﬁcation
(Fig. 5c). The association between morphological diversiﬁcation
and poor prognosis was reproducible in an independent valida-
tion set of HGSOC with high lymphocytic inﬁltration (n= 29,
Fig. 5d). In contrast, none of the clinical variables tested,
including debulking, age and stage, as well as lymphocyte abun-
dance, was associated with OS or RFS within this subtype
(Table 2).
To further interrogate the relationship between immune
ecology and cancer morphological diversiﬁcation, we subse-
quently performed spatial analysis within each tumor, and
identiﬁed a negative spatial correlation between morphological
diversiﬁcation and zonal lymphocyte abundance that was
visually subtle but statistically signiﬁcant (p= 0.001, Jonc-
kheere trend test, Fig. 5e–f). Therefore, we speculated that
diversifying cancer cells evolved immune evasion to overcome
the high level of immune selective pressure in this subtype. We
ﬁrst sought to identify molecular features that could inform the
underlying biology. However, diversiﬁcation was not associated
with Arm/Chrom somatic copy number alteration (SCNA),
cytotoxic immune signature, mutation burden, CTLA4/PD1
expression, or predicted neoantigen burden (Fig. 5g, Supple-
mentary Data 6 and Methods). Nevertheless, only in the
Immunoreactive but not any other subtypes, diversiﬁed samples
had signiﬁcantly higher expression of galectin-3, which
inversely correlated with BRCA1 expression (Fig. 5g, Supple-
mentary Data 2). Since galectin-3 has been previously
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implicated in immune evasion by inducing T cell apoptosis33,34,
we examined its expression within the immune contexture in a
validation sample set. This was achieved by imposing spatial
tessellations from H&E morphological diversiﬁcation analysis
onto galectin-3 IHC images, which enabled direct spatial
analysis to test the relationship between diversiﬁcation and
lymphocyte abundance as spatial variables (Fig. 5h, Methods).
Overall, a negative spatial relationship between galectin-3
expression on cancer cells and CD3+ cells was identiﬁed
(mean Spearman’s rho=−0.40). In addition, we observed
galectin-3 expression at the interface between cancer and
lymphocyte aggregates (Fig. 5i–j, Methods, Supplementary
Data 1). These preliminary data support the role of galectin-3
Table 1 Prognostic value of morphological diversiﬁcation in ovarian cancer using disease-free and overall survival. Only variables
found to be signiﬁcant in univariate analysis were included in multivariate analysis
Type Variable RFS 10 year (n= 440) OS 10 year (n= 511)
HR (CI) p Conc HR (CI) p Conc
Uni Debulking 0.75 (0.58–0.98) 0.031* 0.524 0.74 (0.57–0.96) 0.021* 0.543
Uni Age 1.01 (0.99–1.02) 0.327 0.531 1.02 (1.01–1.03) 0.0004** 0.599
Uni Stage 0.88 (0.52–0.42) 0.266 0.537 1.07 (0.48–0.34) 0.34 0.555
Uni Stromal-high 1.50 (1.13–2.00) 0.005* 0.515 1.22 (0.90–1.64) 0.203 0.515
Uni Lymphocyte-high 0.74 (0.55–0.99) 0.041* 0.521 0.66 (0.48–0.91) 0.01* 0.535
Uni Immunoreactive 0.67 (0.5–0.92) 0.013* 0.535 0.7 (0.5–0.96) 0.035* 0.518
Uni Diversiﬁcation 1.28 (1.01–1.61) 0.038* 0.518 1.45 (1.14–1.85) 0.0022* 0.538
Multi Debulking 0.73 (0.56–0.95) 0.027* 0.557 0.77 (0.59–1.02) 0.064 0.622
Age - - 1.02 (1.01–1.03) 0.0003**
Stromal-high 1.21 (0.89–1.64) 0.22 – –
Lymphocyte-high 0.74 (0.53–1.04) 0.08 0.70 (0.50–0.97) 0.034*
Diversiﬁcation 1.17 (0.92–1.51) 0.193 1.32 (1.02–1.71) 0.03*
Diversiﬁcation, patients with at least one diversiﬁcation zone; Uni, univariate Cox regression; Multi, multivariate Cox regression; Conc, concordance; HR, hazard ratio; CI, conﬁdence interval
*p < 0.05; **p < 0.01
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diversiﬁcation. h Boxplots showing the differences in BRCA1 and RAD54L expression according to the three patient groups in G
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as a potential immune suppressor in HGSOC, which warrants
further investigation.
Discussion
In this study, we investigated the spatial heterogeneity of cancer
cell nuclear morphology in HGSOC. This led to the identiﬁcation
of tumor molecular, spatial and ecological forces that could
inﬂuence morphological diversiﬁcation over space. Under-
standing morphological diversity within the spatial context of
ecological environment was fundamental to the discovery of
Darwinian evolution. However, studying complex morphology of
cancer cells within the tumor microenvironment is particularly
challenging, due to the high microscopic complexity in human
tumors and limitations in model systems in representing this
complexity. By developing a systems approach to deﬁne mor-
phological diversiﬁcation of cancer nucleus, we demonstrated that
the presence of morphologically diverse cancer cells predicted
poor overall survival, an observation that cannot be explained by
known clinical and genetic factors in HGSOC. About half of the
samples contained diversiﬁed zones, and within this subset,
increased number of such zone did not further correlate with
survival, suggesting that risk did not increase with abundance but
pertained to the presence of morphologically diverse cells. This is
in line with the paradigm that cancer evolution is often driven by
rare but signiﬁcant events, for example minor subclones that
drive progression and resistance35. In addition, when morpho-
logical data were averaged for all nuclei within the tumor, no
prognostic value was found, underscoring the importance of
examining the spatial heterogeneity but not tumor average of
cancer morphology.
Morphological diversiﬁcation was associated with dysregula-
tion of LMNA, NUP88, and NUP153, which are key genes in
maintaining nuclear envelope architecture and structural integ-
rity2,36–38, but not Lamin B1/B2. This may be explained by the
speciﬁcity of the nuclear pore protein NUP88 in binding the tail
domain of LMNA but not of Lamin B1/B239. The data points
towards the disruption of NUP88 functions in diversiﬁed samples,
which can induce aneuploidy formation and tumorigenesis40. In
addition, depletion of NUP153 can result in impaired post‐mitotic
assembly of the LMNA, leading to a polymorphic, lobular nuclear
shape36,37. Therefore, these molecular data support the biological
relevance of morphological diversiﬁcation.
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Furthermore, our ﬁndings highlight morphological diversiﬁ-
cation as a BRCA1-related process of disease progression in
HGSOC. Concordant down-regulation of key DNA repair genes
was identiﬁed in diversiﬁed samples. RAD54L, FANCG, BRCA1,
and DNA damage checkpoint CHEK1 were among the most
signiﬁcant genes in differential expression analysis and formed a
co-expression gene module. FANCG is one of the six genes
associated with Fanconi anemia that governed the Fanconi ane-
mia-BRCA (FANC-BRCA) pathway together with BRCA1/241.
Disruption of this pathway can induce cisplatin resistance41,
providing a potential explanation for the poor prognosis of
morphologically diverse samples. Paradoxically, deﬁciency of
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RAD54L, CHEK1, and BRCA1 is known to induce sensitivity to
PARP inhibition and correlate with good prognosis, due to their
involvement in the repair of double-strand breaks by homologous
recombination42,43. However, BRCA-WT patients with diversiﬁ-
cation had signiﬁcantly lower BRCA1 and RAD54L expression
and worse overall survival, even when compared to the BRCA-
MUT group. Therefore, although the association between BRCA1
and tumor morphology has been previously reported44, mor-
phological diversiﬁcation represents a novel subtype with dysre-
gulated DNA repair functions and is urgently in need of new
treatment strategies.
In addition, our proposed morphological features of HGSOC,
identiﬁed using fully automated tumor spatial analysis, provided
independent prognostic value to existing prognostic features of
HGSOC such as lymphocytic inﬁltration and mutation burden.
Together, these results support the development of a new clinical
test to identify high-risk patients by building on the biological
relevance and interactions among the tumor microenvironment,
cancer morphology and genetics. We postulated that evasion of
immune recognition could be responsible for the poor prognosis
of morphologically diverse tumors. In the Immunoreactive
subtype, morphological diversiﬁcation correlated with poor
prognosis, despite an increase of lymphocytes including plasma
and naïve B cells that were favorable prognosticators in
HGSOC45–47. While none of the clinical variables, SCNA,
mutation burden or checkpoint expression can explain this dif-
ference in prognosis, we uncovered a negative spatial relationship
between diversifying cancer cells and immune inﬁltration, indi-
cating immune evasion in localized tumor zones. This was
achieved by examining spatial association between morphologi-
cal diversiﬁcation and lymphocytes within each tumor. Hence,
we demonstrated that spatial analysis performed in human
tumors, based on the emerging concept, space as a surrogate, can
be a useful tool for maximizing inference about ecological
processes20.
Increased expression of galectin-3 in Immunoreactive samples
supports a speculative theory of immune evasion for diversifying
cells. We uncovered preliminary evidence that indicates a role of
galectin-3 in immunosuppression in HGSOC, in line with its
known function in inducing T cell apoptosis in melanoma34. Our
quantitative data, while limited by access to small validation
cohorts, demonstrated a negative spatial relationship between
galectin-3 expression and CD3+ cell inﬁltration. These results
call for further investigations to elucidate the mechanism by
which diversifying ovarian cancer cells mediate and inﬂuence
immune escape. Taken together, our data support a model in
which a subpopulation of cancer cells, morphologically diversiﬁed
in shape, is capable of immune evasion within an immune-hot
tumor. Such cancer cells may co-evolve within a locally immu-
nosuppressive tumor microenvironment, bypassing immune
surveillance and promoting disease progression as a consequence.
Identifying factors driving immune escape in these tumors will
lead to improved understanding in immunosuppression and
advances in immunotherapy for maximum therapeutic gain in
HGSOC.
Methods
Patient selection. This study included 514 patients with International Federation
of Gynecology and Obstetrics (FIGO) stage II-IV HGSOC from TCGA, for whom
H&E-stained whole-tumor sections from treatment-naïve tumor specimens were
available. All specimens were obtained with consent from the relevant institutional
review board participated in TCGA. Samples were split into a discovery cohort that
included the two biggest centers (University of Pittsburgh and Memorial Sloan
Kettering, n= 159) and a validation cohort (remaining centers, n= 355). After
surgery, all patients received a platinum agent and 94% of patients also received a
taxane. Clinical parameters included OS and RFS, age, recurrence, FIGO stage,
debulking and platinum sensitivity status (Table 3). OS was censored at the date of
death or, for living patients, the date of last contact. RFS was deﬁned as the interval
from the date of initial surgical resection to the date of progression, date of
recurrence, or date of last known contact if the patient was alive and had not
recurred. For validating survival analysis in the Immunoreactive subtype, a set of
HGSOC samples (n= 29) with prominent immune inﬁltration was used17. For
IHC experiments, a second validation set of treatment naïve, stage-matched
Table 2 Prognostic value of morphological diversiﬁcation in the Immunoreactive subtype
Type Variable RFS 10 year OS 10 year
HR (CI) p Conc HR (CI) p Conc
Uni Diversiﬁcation 1.94 (1.1–3.44) 0.023* 0.575 1.93 (1.02–3.65) 0.044* 0.528
Uni Debulking 1.01 (0.54–1.92) 0.97 0.498 0.71 (0.37–1.36) 0.31 0.578
Uni Age 0.98 (0.96–1.01) 0.227 0.501 1.02 (0.99–1.05) 0.073 0.604
Uni Stage 1.22 (0.44–3.41) 0.707 0.512 1.77 (0.74–4.22) 0.189 0.534
Uni Lymphocyte abundance 0.86 (0.49–1.5) 0.588 0.52 0.85 (0.47–1.54) 0.596 0.561
* p o 0.05
Fig. 5 Subtype-speciﬁc analysis of morphological diversiﬁcation identiﬁes potential immune evasion in the Immunoreactive subtype. a Swarmplot to
illustrate the difference in lymphocyte abundance according to morphological diversiﬁcation within the Immunoreactive subtype. b Difference in immune
composition according to diversiﬁcation using CIBERSORT. Proportions of naïve B cells were small and therefore invisible. c Kaplan-Meier curves to
illustrate the difference in OS and RFS according to diversiﬁcation in Immunoreactive patients. d Kaplan-Meier curves to illustrate the difference in OS and
RFS according to diversiﬁcation in a validation set of 29 HGSOC with high lymphocytic inﬁltration. Color scheme follows c. e Violin plot showing a visually
subtle spatial trend of decreased lymphocytic inﬁltration in diversiﬁed zones compared with their immediate neighborhood and the rest of the tumor.
f Schematic drawing illustrating decreased lymphocytic inﬁltration in the diversiﬁcation zone, despite an accumulation of lymphocytes in the immediate
neighborhood. g Differences in Arm/Chrom SCNA, cytotoxic immune signature score, CTLA and PD1 expression, mutation burden, neoantigen burden,
BRCA1 and galectin-3 gene expression in samples with/without diversiﬁcation. h An illustrative example of spatial correlation analysis of galectin-3
expression and morphological diversiﬁcation. Spatial tessellations from H&E morphological diversiﬁcation analysis were superimposed onto a galectin-3
IHC image of a serial slide. Only zones containing galectin-3 positive cells were shown for illustrative purpose. Red points denote zones without
diversiﬁcation, and green points denote zones with diversiﬁcation. Boxplot shows the difference in galectin-3 expression between all diversiﬁed and non-
diversiﬁed zones across validation samples. i 3D spatial map to illustrate the spatial relationship between galectin-3 and CD3+ cells in a sample. j An
illustrative example of galectin-3 expression at the cancer-lymphocyte interface. Scale bar shows 30μm
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samples (n= 7) was obtained with appropriate ethical approval under the Royal
Marsden Hospital NHS Foundation Trust study CCR3705 (Supplementary Data 1).
IHC staining. All staining was performed on the Leica Bond III platform using
Leica Bond Polymer Reﬁne Detection (Leica, DS9800). Blocking of endogenous
peroxidase and non-speciﬁc staining was performed as per kit instructions. Fol-
lowing on-board dewax, and epitope retrieval (HIER) where necessary, primary
antibody was applied for 15 min, followed by rabbit anti-mouse post-primary and
anti-rabbit polymer for 8 min each, all at ambient temperature. Epitope retrieval
was performed on-board at 99 C using either Leica Epitope Retrieval Solution 1 or
2 (Leica, AR9961, AR9640; low and high pH solutions respectively), for the times
shown below.
Protocols for individual antibodies were as follows: CK7 (Leica, mouse clone
RN7, cat. PA0138) used as supplied (ready-to-use reagent, with no further
dilution), HIER with ER2 for 20 min; CD3 (Leica, mouse clone LN10, cat. NCL-L-
CD3-565), used at a dilution of 1/100, HIER with ER2 for 20 min; CD8 (Leica,
mouse 4B11, cat. PA0183) used as supplied, HIER with ER2, 20 min; CD20
(Agilent Technologies, mouse L26, cat. M075501-2) used at 1/100, HIER with ER1,
20 min; SMA (Leica, mouse sm-1, cat. PA0943) used as supplied, no epitope
retrieval required; Galectin-3 (Leica, mouse 9C4, cat. PA0238), used as supplied,
HIER with ER2, 20 min.
H&E image analysis. 514 H&E whole-tumor section images were subjected to fully
automated image analysis for single-cell classiﬁcation at a resolution of 0.5 microns
per pixel. Each sample was split into non-overlapping tiles with a size 2000 × 2000
pixels using bfconvert from the open microscopy environment48. Stain normal-
ization was performed using a nonlinear mapping approach24 to accommodate the
high staining variability in the samples resulting from variations in tissue pre-
paration and stain reactivity. Single cell detection and classiﬁcation were performed
using open source R package CRImage23 with an ovarian cancer cell classiﬁer17,49.
In brief, watershed segmentation for hematoxylin positive nuclei was performed for
cell detection, and classiﬁcation was based on a support vector machine50 with 97
morphological and textural features. Validation of the automated cell identiﬁcation
was performed using n= 894 single cell annotations (stromal cells n= 209, cancer
cells n= 501 and lymphocytes n= 184) from 32 images provided by a pathologist
(DNR) blinded to image analysis results, pathological scoring of cancer and stromal
cells, gene expression and copy-number data provided by TCGA51.
Validation of H&E image analysis with serial IHC sections. We developed an
image analysis pipeline to validate H&E image analysis using multiple serial IHC
sections, which combined automated image registration, IHC image and spatial
analysis. In brief, multiple sections were cut and placed in the same orientation on
the slides, with the H&E midway through the series. The remaining sections were
stained with CK7, CD3, CD8, CD20, SMA, galectin-3, respectively. These were
digitalized and spatially aligned to H&E using an image registration algorithm52.
The accuracy of image registration was evaluated (average Dice coefﬁcient= 0.91).
Results of H&E-IHC correlation were reported as sample-level cross-correlations
between the two assays and within-sample spatial correlations at a spatial resolu-
tion of 64 μm (~8–10 cells) (Supplementary Data 1).
IHC image registration to H&E was performed using a two-stage approach: an
initial rigid alignment followed by a non-linear reﬁnement. The ﬁrst stage of the
registration was performed by aligning the external boundaries of the tissue
sections52. The initial rigid registration was more likely to be inaccurate at high
resolution, due to non-linear physical distortions that occur during sectioning. The
second stage process corrected for this by performing a reﬁnement procedure at
high resolution to generate a non-linear registration transformation, based upon
the initial rigid registration. The reﬁnement was a local rigid alignment of salient
tissue structures, such as nuclei clusters, and was performed on 500 × 500 pixel
regions, sampled at a resolution of 0.46 microns/pixel. Coordinates of the corners
of each region of interest were used as reference points to ﬁnd the best-ﬁt non-
linear transformation. Here a 4th degree polynomial transformation was used. The
accuracy of image registration was assessed. We used the DICE coefﬁcient to
measure the overlap of tissues after registration (Supplementary Data 1). DICE
similarity coefﬁcient is a spatial overlap index and a reproducibility validation
metric, deﬁned as twice the overlap area divided by the sum of two tissue areas. Its
value ranges from 0, indicating no spatial overlap between two sets of binary
results, to 1, indicating complete overlap.
All IHC sections were ﬁrst mapped onto the H&E section using the
transformations generated from the registration process. Stain separation53 was
applied to the registered RGB images to extract the intensities of the hematoxylin
and IHC stains. Thresholding was applied to IHC stain channel to identify regions
of positivity for each marker according to controls. Tissue regions belonging to the
slide background, tissue folding, staining artefacts were not considered while
calculating IHC scores. Automated IHC scoring was performed on 10 × 10 regions
of interest, sampled at a resolution of 6.4 microns/pixel. Regions were scored as the
percentage of positive cells. In the case of galectin-3 scoring, instead of a 10 × 10
neighborhood, all the pixels that were inside the edges of a particular Voronoi
tessellation were considered to calculate the positivity score. For sample-level
analysis, regional scores were averaged.
We then estimated CK7, CD3, and SMA positivity and calculated their spatial
correlation with cancer, lymphocyte and stroma ratios estimated from the H&Es,
respectively. We observed a positive spatial correlation between CK7 and cancer
ratio (average Pearson corr= 0.74 ( ± 0.03)) calculated from 7 IHC samples.
Similarly, we observed a positive spatial correlation between CD3 positivity and
lymphocyte (average Pearson corr= 0.67 ( ± 0.09)) calculated from 7 IHC samples.
Lastly, we observed a positive spatial correlation between for SMA, positivity and
stroma ratio (average Pearson corr= 0.70 ( ± 0.06)) calculated from 7 IHC
samples. The lowest correlation was observed between lymphocyte and CD3, as
expected, since only a subset of lymphocytes were T cells. Because the CD20 stain
was largely negative across all these samples, and CD8 was mainly used to conﬁrm
its presence among CD3+ cells, we did not use them for quantitative analysis.
Spatial analysis of tumor morphology. Spatial partitioning of tumor sections into
tumor regions was achieved using Voronoi tessellation. Because Voronoi tessella-
tion mimics naturally emerged patterns, it is therefore particularly useful for stu-
dies of ecology54, and we have recently demonstrated its applicability in histology
analysis20,55. Randomly selected cancer cells were used as seeds to create polygons
that contain all their closest neighbors. Let K be a set containing all cancer cells,
and let (Ck)k∈K be the coordinates of a cancer cell k. A Voronoi region Rk generated
by cancer cell Ck contains all cells P that are (1) not seeds and, (2) closer to Ck than
to any other seed Cj, j ≠ k. Let d(Qi,Qj) be the Euclidean distance function between
Table 3 Patient clinicopathologic characteristics stratiﬁed
by presence/absence of morphological diversiﬁcation
Morphological diversiﬁcation
Factor Present Absent P
Number 276 238
Analyzed subimages 57109 84322
Cancer cells 55,059,416 51,561,042
Lymphocytes 10,303,767 8,979,007
Stromal cells 12,266,456 9,010,693
Age 0.91
Median 58 59
Range (36–87) (26–87)
Death 0.003*
No 132 (47.8%) 92 (38.7%)
Yes 144 (52.2%) 145 (60.9%)
Unknown 0 (0%) 1 (0.4%)
Recurrence 0.002*
Yes 163 (59.1%) 126 (52.9%)
No 2 (0.07%) 12 (5%)
Unknown 111 (40.2%) 100 (42%)
Molecular subtype 1.3 × 10
−06*
Differentiated 95 (34.4%) 33 (13.9%)
Immunoreactive 40 (14.5%) 60 (25.2%)
Mesenchymal 68 (24.6%) 34 (14.3%)
Proliferative 73 (26.4%) 56 (23.5%)
Unknown 0 (0%) 55 (23.1%)
FIGO stage 0.018
IIa 1 (0.4%) 2 (0.8%)
IIb 3 (1.1%) 1 (0.4%)
IIc 6 (2.2%) 13 (5.5%)
IIIa 6 (2.%) 0 (0%)
IIIb 10 (3.6%) 13 (5.5%)
IIIc 199 (72.1%) 180 (75.6%)
IV 48 (17.4%) 28 (11.8%)
Unknown 3 (1.1%) 1 (0.4%)
Debulking 0.38
Optimal 170 (61.6%) 159 (66.8%)
Suboptimal 74 (26.8%) 57 (23.9%)
Unknown 33 (11.6%) 22 (9.2%)
Platinum status 0.23
Resistant 55 (19.9% 28 (11.8%)
Sensitive 110 (39.9%) 79 (33.2%)
Unknown 111 (40.2%) 131 (55%)
*p < 0.05
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two cells Qi and Qj, then
Rk ¼ x 2 Pjd x;Ckð Þ  d x;Cj
 
;8j≠k
n o
: ð1Þ
The aim of spatial tessellation is to divide tissue areas into small regions. We
have previously evaluated different methods for spatial tessellation, the most
common ones being square and Voronoi56. Here we chose to use Voronoi due to
its property in mimicking naturally arising pattern and generating a more
uniformly distributed number of cells per region, compared with square
tessellation. We used randomly selected cancer cells as seeds, such that the number
of cancer cells from the Voronoi regions follows a normal distribution. Because the
morphology of cancer cells within each spatial region was the focus here, we did
not speciﬁcally account for vessels or clear areas.
Informally, this means that for each cancer cell selected as a seed, the
corresponding Voronoi region consists of all cells that are closer to this cancer cell
(seed) than to any other seed in the tissue. The number of cancer cells N selected as
seeds scaled non-linearly with tissue area and was computed by
N ¼ Tissue area
1
2
3
; ð2Þ
resulting in an average of 527.5 zones per tumor. Equation 2 determines the
number of regions and, by choosing cancer cells as seeds, also ensures that there are
cancer cells within the regions. In addition, cancer-dense regions are more likely to
have seeds sampled. Therefore, it helps dissect regions with densely packed cancer
cells. Because the main objective of this study is to identify spatial diversiﬁcation of
cancer nucleus morphology, the size of region should scale with the tissue size
instead of the number of cancer cells, to avoid bias towards tissue size. For example,
if it scales with the number of cancer cells, for tumors with signiﬁcant ﬁbrotic
content, there will be fewer regions and therefore results would skew the spatial
analysis result: existing spatial diversiﬁcation in cancer morphology may not get
detected due to low spatial resolution.
Statistical identiﬁcation of morphological diversiﬁcation zones. Diversiﬁcation
zone identiﬁcation was carried out by computing local Moran’s I57, an indicator
of spatial autocorrelation for a speciﬁc spatial location. Local Moran’s I was
developed for the identiﬁcation of spatial hotspots or outliers57, and has been
extensively used in ecology due to several outstanding properties compared with
other methods58–60. When applied to the shape feature data of cancer nuclei in
conjunction with their spatial locations, it can identify tumor regions containing
cancer nuclei with signiﬁcantly different morphology compared with other regions.
Local Moran’s I for a region i is deﬁned as
Ii ¼ ϒi  ϒi
 Xm
j¼1
wij ϒj  ϒi
 
; ð3Þ
where ϒi is the variability of the shape feature for all cancer cells Ci, j=1…n in Ri
derived by
ϒi ¼ SD
pCj
2
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
π  aCj
p
 !
; 8j 2 f1; ¼ ; ng ð4Þ
where SD is the standard deviation function, pCj is the perimeter of the nucleus of
the jth cancer cell, aCj the nuclear area of the jth cancer cell and n the total amount
of cancer cells within the region Ri. ϒ is the average of Yi,i∈{1..m} for all regions in
the neighborhood of region Ri and wij is the spatial weight of the connection
between i and j. wij is 1 if i is a neighbor region of j, and 0 otherwise. A region is a
neighbor to Ri if they share a common edge or point. Local Moran’s I allows to
perform signiﬁcance test against the null hypothesis of no spatial association, that
is, spatial randomness. Following Anselin57, the signiﬁcance test was carried out by
comparing the standardized Moran’ I statistics, z-scores,
zi ¼
Ii  E Ii½ ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
Var Ii½ 
p ; ð5Þ
to the standard normal distribution, using p= 0.05 as a threshold for signiﬁcance
and adjusted with False Discovery Rate. This determined whether a zone presents
signiﬁcantly different cancer nuclear morphology as compared to the global mean
and neighboring zones in the tumor. In Anselin57, Monte Carlo permutations were
recommended to obtain more accurate p-values compared with analytical methods,
as illustrated with an example study on 42 African nations. We have compared an
implementation of the Hope methodology61 with analytically obtained p-values for
cancer morphological diversiﬁcation and found no signiﬁcant difference or
advantage in using Monte Carlo simulations, possibily due to the large number of
observations obtained per tumor samples (on average 527.5 zones per tumor).
Pathological inspection. 50 samples were inspected by a pathologist. In some
cases (roughly 40%), increased pleomorphism could be observed in most of the
diversiﬁed regions. For the remaining cases there was no immediately obvious,
uniform feature that differentiates these two types of regions, suggesting that image
analysis can identify visually subtle features of tumor nuclear morphology.
Molecular data analysis. ESTIMATE62 and ABSOLUTE63 tumor purity data were
downloaded from64. ESTIMATE uses gene expression proﬁles of 141 immune
genes and 141 stromal genes to estimate tumor purity, stromal and immune scores
(based on TCGA Agilent array-based expression proﬁles of ovarian cancer n= 417
used for ovarian cancer in the original publication). ABSOLUTE uses somatic
copy-number data for inferring tumor purity. Copy number (n= 463), gene
expression (n= 455), methylation (n= 433), mutation data and mutation burden
as the total number of somatic mutations (n= 297) were obtained from the Broad
Institute and cBioportal65,66. Differential gene expression analysis of samples with
and without diversiﬁcation was performed using the R (v3.3.1) package limma67
(v3.28.21) available via Bioconductor68. Gene set enrichment analysis was per-
formed using the R package HTSanalyzeR (v2.26.0). Multiple testing correction was
performed using False Discovery Rate69. Immune cell subset analysis was per-
formed using CIBERSORT32 and the most variable probe for each gene was
selected according to standard deviation. Gene expression was then deconvoluted
using the LM22 signature matrix32, which contains 547 genes for the identiﬁcation
of 22 hematopoietic cell types. Statistical signiﬁcance was assessed by generating p-
values from 200 permutations. Only the patient subset with immune abundance
greater than the median immune abundance and with internal ﬁltering step p ≤
0.05 was considered for deconvolution analysis. Hypergeometric test was used for
copy number and mutation data analysis to identify speciﬁc alterations or muta-
tions enriched in morphologically diverse samples with multiple testing correc-
tions. Only Immunoreactive subtype contained sufﬁcient number of samples after
ﬁltering. BRCA1 epigenetically silenced group was derived by clustering BRCA1
expression and methylation data using Gaussian mixture models70 following18.
Galectin-3 expression and its relationship with CD3 expression and mor-
phological diversiﬁcation. In all of these samples, we observed a negative spatial
correlation between galectin-3 expression and CD3 expression. To avoid the cor-
relation analysis being confounded by the spatial segregation of tumor and stroma,
only regions with at least 30% but no more than 70% tumor were used. We further
carried out spatial correlation analysis of tumor content and galectin-3 expression
but found no correlation (corr= 0.019), thereby excluding the possibility that the
correlation between CD3 and galectin-3 was due to stroma-tumor spatial division.
Correlation analysis between galectin-3 and CD3 was carried out using all regions
as such in a sample.
H&E morphological diversiﬁcation analysis was performed as previously
described. 2/7 samples did not contain any diversiﬁed regions. Spatial tessellation
derived from this analysis was imposed onto galectin-3 IHC images after
registration. For each sample with diversiﬁcation present, galectin-3 expression was
quantiﬁed for each region. All regions across 5/7 samples were pooled together for
testing the difference in galectin-3 expression as shown in Fig. 5h. Average galectin-
3 expression in diversiﬁed and non-diversiﬁed regions for each sample was listed in
Supplementary Data 1.
Survival analysis and statistical tests. Statistical analyses were performed in R.
Survival analysis was performed using the Kaplan-Meier estimate and the log-rank
test. Cox proportional hazards model was used for univariate and multivariate
survival analysis. Effects were expressed as hazard ratios (HR) with 95% conﬁdence
intervals (CI). Kruskal–Wallis test was used to compare sets of continuous values,
Fisher’s exact test for categorical variables. The abundance of stromal cells/lym-
phocytes was quantiﬁed as the percentage of stromal cells/lymphocytes in all cells.
Microenvironmental subtypes were identiﬁed based on the percentage of lym-
phocytes and stromal cells for each tumor. Lymphocyte-high subtype was deter-
mined by high lymphocyte abundance ( ≥75%) and low stromal cell abundance
(≤25%), such that the number of patients was similar to that of the Immunor-
eactive subtype. Similarly, the Stromal-high subtype was determined as samples
with low lymphocyte abundance (≤25%) and high stromal cell abundance (≥75%).
With continuous variables, a range of cutoffs at 30–70 percentiles at 1% interval
was searched to identify cutoffs that resulted in difference in survival. Zonal dif-
ference in lymphocytic inﬁltration was computed using all diversiﬁcation zones,
their immediately adjacent neighboring zones and remaining zones, and the
Jonckheere trend test was used for testing spatial trends.
Neoantigen prediction. For 40 of the patients in the immunoreactive subtype, we
could download whole exome sequencing data from the TCGA website. Reads
extracted from the TCGA bam ﬁles were realigned to human build GRCh37
(hs37d5). Our protocol for annotating neoantigens is constituted of the following
steps: (i) variant calling in tumor and germline samples for each patient; (ii)
annotation of neopeptides generated by somatic variants; (iii) prediction of
patients’ HLA-types; (iv) prediction of neoantigens using neopeptides from (ii) and
HLA-types from (iii) as input. Hereafter, we describe in details the different steps.
1. Variant calling
: we called both germline and somatic variants using a combination of
MuTect271 and Platypus72. We ﬁrst ran MuTect2 (MuTect2 -R < hs37d5.fa
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> -I:tumor < tumor_bam_ﬁle > -I:normal < normal_bam_ﬁle > –dbsnp <
dbsnp_132_b37.leftAligned.vcf > –cosmic < hg19_cosmic_v54_120711.vcf
> -o < mutect_vcf_ﬁle > ) and then used MuTect2 calls as priors for a joint
normal-tumor Platypus call (platypus callVariants–refFile≤hs37d5.fa
> –bamFiles≤normal_bam_ﬁle, tumor_bam_ﬁle > –output≤somatic_vcf_ﬁle
> –source≤mutect_vcf_ﬁle > –minPosterior= 0–getVariantsFromBAMs=
1–logFileName ≤log_ﬁle > –verbosity= 1). From the output of Platypus, we
assigned germline variants as follows: they had a PASS in the FILTER column
of the Platypus output, genotype quality GQ≥10, germline sample genotype
different from “0/0”, germline coverage ≥10 and at least one germline variant
read. If more than one alternative variant satisﬁed these conditions and
appeared in the Platypus-assigned genotype, we considered only the one that
had the highest allele frequency. We ﬁltered out variants found in segmental
duplication regions (genomicSuperDups.bed.gz). From the output of Platypus,
we assigned somatic variants as follows: we excluded variants that in the
corresponding germline sample had coverage lower than 10, genotype other
than “0/0”, genotype quality GQ < 10 or one or more reads carrying a variant.
Somatic indels were retained if they had PASS or alleleBias in the FILTER
column of the Platypus output; all other somatic variants we considered (see
below for a complete list) were retained if they had any among PASS,
alleleBias, Q20, QD, SC, and HapScore in the FILTER column. Further, any
somatic variant had to have in the tumor sample: genotype different from
“./.”, coverage≥10, at least 3 reads carrying the variant. If more than one
alternative variant satisﬁed these conditions, we considered the one that had
the highest allele frequency among those that appeared in the Platypus-
assigned genotype or, if none appeared in the Platypus-assigned genotype,
simply the one with the highest allele frequency. Next, we ﬁltered out somatic
variants with tumor content-adjusted allele frequency <0.15. We ﬁltered out
variants found in segmental duplication regions (genomicSuperDups.bed.gz).
2. Neopeptide generation
: for neopeptide generation, we considered the following protein
sequence–modifying variants (following the VEP73 classiﬁcation: variant_ef-
fect_predictor.pl -i < input_vcf_ﬁle > -o < output_vep_vcf_ﬁle > –cache–dir_
cache < dir_cache > –port < port# > –everything–force_overwrite–vcf): mis-
sense_variant, inframe_insertion, inframe_deletion, frameshift_variant, sto-
p_lost and stop_gained. However, variants that additionally featured one or
more among splice_acceptor_variant, splice_donor_variant, start_lost or
stop_retained_variant annotation terms, were discarded. As a source for
protein sequences we used the ﬁle Homo_sapiens.GRCh37.75.pep.all.fa
downloaded from the ENSEMBL website (http://ftp.ensembl.org/pub/
release-75/fasta/homo_sapiens/pep/). Neopeptides of lengths 8–11 were
generated using in-house scripts according to the following protocol. For
each somatic variant (see categories above) falling in a canonical transcript
(canonical transcripts annotated following VEP), we ran a sliding window on
the corresponding mutated protein sequence to generate all peptides of length
8–11 spanning the variant. A number of cases deserved special attention. If
one or more additional variants (somatic or germline) were found within 8–11
positions of the somatic variant under consideration, we had to decide
whether or not the neopeptide generated would carry none, some or all of the
additional variants. Here, to simplify things, we assumed all variants (be it
somatic or germline) to be ‘in phase’ with each other and with the same
zygosity. This meant that if additional variants were found within 8–11
positions of a somatic variant, the neopeptides we generated carried all the
variants (both somatic and germline) that were present in the protein region
they spanned. Neopeptides corresponding to somatic stop_lost and frameshift
variants were generated by modifying the cDNA sequence of the canonical
transcript (as found in http://ftp.ensembl.org/pub/release-75/fasta/
homo_sapiens/cdna/Homo_sapiens.GRCh37.75.cdna.all.fa.gz) according to
the observed variant and generating the frame-shifted protein sequence until
a stop codon was found or the end of the cDNA sequence was reached. We
manually checked for cases in which 3_prime_UTR variants could affect the
resulting neopeptides. Further, cases of frameshift and stop_lost variants
where additional variants were present within the same transcript (e.g. a
second frameshift variant) as well as cases where two or more neighboring
variants overlapped (i.e. they affected at least one identical amino acid
position) were manually inspected to determine the frame-shifted neopeptides
that had to be generated. Finally, neopeptides generated by somatic mutations
in a protein were excluded if they were found elsewhere in the germline
version of the same protein (modiﬁed taking into account, if present, any
germline missense mutation and inframe indel; if two or more germline
variants were found within 8–11 positions of one another, we considered as
germline peptides the ones carrying all the germline mutations that were
present in the protein region they spanned). The in-house python scripts we
used to generate neopeptides are available upon request.
3. HLA types
: HLA-A, HLA-B and HLA-C types were predicted using the program
Polysolver74 run on normal samples (shell_call_hla_type < normal_bam_ﬁle
> Unknown 1 hg19 STDFQ 0 < output_ﬁle > ).
4. Neoantigen prediction: neoantigens were predicted using the program
netMHCpan-3.075. For each patient, we ran netMHCpan-3.0 against their
list of neopeptides as many times as the number of their predicted HLA-types
(minimum three and maximum six different types per patients) (netMHCpan
-p < list_of_peptides_ﬁle > -a < 4-digit_hla_type > > < output_ﬁle > ). For
each patient we generated 4 (possibly overlapping) lists of neoantigens
(Supplementary Data 6): high-afﬁnity binders (<500 nM), strong binders
(rank<0.5; note that rank is HLA type-speciﬁc), weak binders (rank between
0.5 and 2.0) and strong+weak binders (rank<2.0). Doubles were not counted
in any list (i.e. a peptide that was predicted to be a e.g. strong binder for more
than one of the patient’s HLA-types was counted only once) and weak binders
for an HLA-type were not counted if they also appeared as strong binders for
a separate HLA type of the same patient
TCGA ids for the 40 patients for which we predicted neoantigens: TCGA-61-
2012, TCGA-61-1995, TCGA-24-2288, TCGA-24-2267, TCGA-24-1474, TCGA-
20-0987, TCGA-13-1410, TCGA-09-2051, TCGA-61-2002, TCGA-57-1994,
TCGA-29-2427, TCGA-25-2396, TCGA-24-2281, TCGA-24-2261, TCGA-13-
1496, TCGA-13-0805, TCGA-13-0795, TCGA-04-1348, TCGA-61-2104, TCGA-
61-2094, TCGA-24-2290, TCGA-24-1551, TCGA-23-1123, TCGA-13-0885,
TCGA-61-2000, TCGA-59-2351, TCGA-25-1313, TCGA-23-2084, TCGA-23-
2079, TCGA-23-2077, TCGA-20-0991, TCGA-13-2060, TCGA-13-0897, TCGA-
13-0723, TCGA-09-2044, TCGA-04-1357, TCGA-25-2392, TCGA-13-1484,
TCGA-13-0760, TCGA-09-0366.
Code availability. CRImage is available from Bioconductor. R code for performing
relevant analyses are provided as Sweave ﬁles for reproducibility online yuanlab.
org/software/diversiﬁcation/sweave.pdf.
Data availability
Pathological images and clinicopathological information of the TCGA samples are
available in a public repository from the TCGA Data Portal (https://tcga-data.nci.nih.
gov/tcga/). All other data supporting the ﬁndings of this study are available as part of the
reproducible Sweave package.
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